Nu Skin Enterprises Inc. Cl A

Nu Skin Enterprises develops and distributes a line of beauty and wellness solutions. The company's primary product categories are personal care products and wellness products. The company develops and distributes products in these two categories under its Nu Skin and Pharmanex brands, respectively. The company's personal care products include its skin care devices. The company's skin care devices and related consumables are ageLOC Spa systems and its ageLOC LumiSpa skin treatment and cleansing device. The company's wellness products line includes its LifePak nutritional supplements, ageLOC Youth nutritional supplements and its ageLOC TR90 weight management and body shaping system.
  • TickerNUS
  • ISINUS67018T1051
  • ExchangeNew York Stock Exchange
  • SectorPersonal Goods
  • CountryUnited States
Jonathan Moreland

InsiderInsights Daily Ratings Report: February 22, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Nu Skin Enterprises Inc: 1 director bought

A director at Nu Skin Enterprises Inc bought 10,110 shares at 49.485USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 18, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

With a more favourable environment, NU SKIN ENTERPRISES improves to Slightly Positive

NU SKIN ENTERPRISES (US), a company active in the Personal Products & Services industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date February 16, 2021, the closing price was USD 48.31 and its potential was estimated at USD 77.03.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Nu Skin Enterprises Inc: 1 director bought

A director at Nu Skin Enterprises Inc bought 10,110 shares at 49.485USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 22, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 18, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MarketLine Department

Herbalife Nutrition Ltd. - Strategy, SWOT and Corporate Finance Report

Summary Herbalife Nutrition Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Herbalife Nutrition Ltd. (Herbalife or 'the company') is a provider of nutritional and health products. The company offers weight management, nutrition, sports, energy, fitness and personal care products. Its product portfolio comprises protein shakes; meal replacement, drink mixes;...

With a more favourable environment, NU SKIN ENTERPRISES improves to Slightly Positive

NU SKIN ENTERPRISES (US), a company active in the Personal Products & Services industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date February 16, 2021, the closing price was USD 48.31 and its potential was estimated at USD 77.03.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch